Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: A systematic review

Age and Ageing

Volumn 43, Issue 5, 2014, Pages 604-615

  Fox, Chris ^a   Smith, Toby ^a   Maidment, Ian ^b   Chan, Wei Yee ^a   Bua, Nelson ^a   Myint, Phyo Kyaw ^c   Boustani, Malaz ^d   Kwok, Chun Shing ^e   Glover, Michelle ^a   Koopmans, Imogen ^a   Campbell, Noll ^f  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f PURDUE UNIVERSITY   (United States)

Author keywords

Adverse effect; Anti cholinergic; Anti muscarinic; Cholinergic antagonist; Cognition; Function; Mortality; Older people; Systematic review

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

CHEMICALLY INDUCED; COGNITION; COGNITION DISORDERS; DELIRIUM; DRUG EFFECTS; HEALTH STATUS; HUMAN; MORTALITY; PROGNOSIS; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR; ADULT; ARTICLE; COGNITIVE DEFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; FUNCTIONAL ASSESSMENT; MALE; MINI MENTAL STATE EXAMINATION; PHYSICAL ACTIVITY; PHYSICAL MOBILITY; RATING SCALE; SCORING SYSTEM; SYSTEMATIC REVIEW; WALKING;

CHOLINERGIC ANTAGONISTS; COGNITION; COGNITION DISORDERS; DELIRIUM; HEALTH STATUS; HUMANS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84906877927     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afu096     Document Type: Review

References (59)

1. Ness J, Hoth A, Barnett M, Shorr R, Kaboli P. Anti-cholinergic medications in community-dwelling older veterans: prevalence of anti-cholinergic symptoms, symptom burden and adverse drug events. Am J Geriatr Pharamacother 2006; 4: 42-51.
2. Gurwitz J, Field T, Harrold L. Incidence and preventability of adverse drug events amongst older persons in the ambulatory setting. JAMA 2003; 289: 1107-16.
3. Campbell N, Boustani M, Limbil T et al. The cognitive impact of anti-cholinergics: a clinical review. Clin Interv Aging 2009; 4: 225-33.
4. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Camahan R. A systematic review of amnestic and nonamnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012; 29: 639-58.
5. Fox C, Richardson K, Maidment ID et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59: 1477-83.
6. Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimers Dement 2012. doi: 10.1016/j.jalz.2012.02.005.
7. Campbell NL, Boustani MA, Lane KA et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010; 75: 152-9.
8. Petersen RC, Roberts RO, Knopman DS et al. The Mayo clinical study of aging: incidence of mild cognitive impairment. Alzheimers Dement 2008; 4.
9. Bell J, Mezrani C, Blacker N et al. Anticholinergic and sedative medicines-prescribing considerations for people with dementia. Aust Fam Physician 2012; 41: 45-9.
10. Barber SE, Clegg AP, Young JB. Is there a role for physical activity in preventing cognitive decline in people with mild cognitive impairment?. Age Ageing 2012; 41: 5-8.
11. Wilson NM, Hilmer SN, March LM et al. Associations between drug burden index and mortality in older people in residential aged care facilities. Drugs Aging 2012; 29: 157-65.
12. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
13. Campbell NL, Maidment I, Fox C, Kahn B, Boustani M. The 2012 update to the Anticholinergic Cognitive Burden Scale. J Am Geriatr Soc 2013; 61(Suppl. 1): S142-3.
14. Dyer C, Ashton C, Teasdale TA. Postoperative delirium: a review of 80 primary data-collection studies. Arch Intern Med 1995; 155: 461-5.
15. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. www.ohri.ca/programs/clinical_epidemiology/ oxford.asp
16. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbooks for Systematic Reviews of Interventions. Chichester, UK: Wiley-Blackwell, 2011; 187-242.
17. Agar M, To T, Plummer J, Abernethy A, Currow D. Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study. J Palliative Med 2010; 13: 745-52.
18. Ancelin ML, Artero S, Portet F, Dupuy A-M, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332: 455-8.
19. Boustani M, Hall KS, Lane KA et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc 2007; 55: 1248-53.
20. Caeiro L, Ferro JM, Claro MI, Coelho J, Albuquerque R, Figueira ML. Delirium in acute stroke: a preliminary study of the role of anticholinergic medications. Eur J Neurol 2004; 11: 699-704.
21. Campbell N, Perkins A, Hui S, Khan B, Boustani M. Association between prescribing of anticholinergic medications and incident delirium: a cohort study. J Am Geriatr Soc 2011; 59: 277-81.
22. Cancelli I, Gigli GL, Piani A et al. Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study. J Clin Psychopharmacol 2008; 28: 654-9.
23. Cao Y-J, Mager DE, Simonsick EM et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008; 83: 422-9.
24. Carriere I, Fourrier-Reglat A, Dartigues J-F et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009; 169: 1317-24.
25. Cruce R, Vosoughi R, Freedman MS. Cognitive impact of anticholinergic medication in MS: adding insult to injury?. Mult Scler Relat Disord 2012; 1: 156-61.
26. De Luise C, Lanes SF, Jacobsen J, Pedersen L, Sorensen HT. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007; 22: 267-72.
27. Drag LL, Wright SL, Bieliauskas LA. Prescribing practices of anticholinergic medications and their association with cognition in an extended care setting. J Appl Gerontol 2012; 31: 239-59.
28. Fox C, Livingston G, Maidment ID et al. The impact of anticholinergic burden in Alzheimer's dementia-the LASER-AD study. Age Ageing 2011; 40: 730-5.
29. Gaudreau JD, Gagnon P, Harel F, Roy MA, Tremblay A. Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol 2005; 23: 6712-8.
30. Geller EJ, Crane AK, Wells EC et al. Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Invest 2012; 32: 697-705.
31. Gnjidic D, Le Couteur DG, Naganathan V et al. Effects of drug burden index on cognitive function in older men. J Clin Psychopharmacol 2012; 32: 273-7.
32. Gnjidic D, Cumming RG, Le Couteur DG et al. Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol 2009; 68: 97-105.
33. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56: 2203-10.
34. Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology 2003; 169: 404-11.
35. Hilmer SN, Mager DE, Simonsick EM et al. Drug Burden Index Score and functional decline in older people. Am J Med 2009; 122: 1142-9.
36. Kay G, Crook T, Rekeda L et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317-26.
37. Kersten H, Molden E, Tolo IK, Skovlund E, Engedal K, Wyller TB. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Biol Sci Med Sci 2013; 68: 271-8.
38. Kersten H, Molden E, Willumsen T, Engedal K, Wyller TB. Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes. Br J Clin Pharmacol 2013; 75: 842-9.
39. Kolanowski A, Fick DM, Campbell J, Litaker M, Boustani M. A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia. J Am Med Dir Assoc 2009; 10: 252-7.
40. Koyama A, Steinman M, Ensrud K, Hillier TA, Yaffe K. Ten-year trajectory of potentially inappropriate medications in very old women: importance of cognitive status. J Am Geriatr Soc 2013; 61: 258-63.
41. Kumpula EK, Bell JS, Soini H, Pitkala KH. Anticholinergic drug use and mortality among residents of long-term care facilities: a prospective cohort study. J Clin Pharmacol 2011; 51: 256-63.
42. Lampela P, Lavikainen P, Garcia-Horsman JA, Bell JS, Huupponen R, Hartikainen S. Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study. Drugs Aging 2013; 30: 321-30.
43. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173: 493-8.
44. Luukkanen MJ, Uusvaara J, Laurila JV et al. Anticholinergic drugs and their effects on delirium and mortality in the elderly. Dement Geriatr Cogn Dis Extra 2011; 1: 43-50.
45. Mangoni AA, Munster BCV, Woodman RJ, Rooij SED. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiatry 2013; 21: 785-93.
46. Merchant RA, Li B, Yap KB, Ng TP. Use of drugs with anticholinergic effects and cognitive impairment in communityliving older persons. Age Ageing 2009; 38: 105-8.
47. Pandharipande P, Shintani A, Peterson J et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006; 104: 21-6.
48. Pasina L, Djade CD, Lucca U et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. Drugs Aging 2013; 30: 103-12.
49. Shah RC, Janos AL, Kline JE et al. Cognitive decline in older persons initiating anticholinergic medications. PLoS ONE 2013; 8: 5.
50. Sakakibara R, Tateno F, Yano M et al. Imidafenacin on bladder and cognitive function in neurologic OAB patients. Clin Auton Res 2013; 23: 189-95.
51. Uusvaara J, Pitkala KH, Kautiainen H, Tilvis RS, Strandberg TE. Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: a prospective study. Drugs Aging 2011; 28: 131-8.
52. Uusvaara J, Pitkala KH, Kautiainen H, Tilvis RS, Strandberg TE. Detailed cognitive function and use of drugs with anticholinergic properties in older people: a community-based cross-sectional study. Drugs Aging 2013; 30: 177-82.
53. Wagg AS, Dale M, Tretter R, Stowe B, Compion G. Solifenacin and cognitive function in elderly people with mild cognitive impairment: the SENIORstudy.Eur Urol Suppl 2012; 11: e689-e689a.
54. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009; 8: 615-26.
55. Whalley LJ, Sharma S, Fox HC et al. Anticholinergic drugs in late life: adverse effects on cognition but not on progress to dementia. J Alzheimer's Dis. 2012; 30: 253-61.
56. Wilson NM, Hilmer SN, March LM et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc 2011; 59: 875-80.
57. Yeh Y-C, Liu C-L, Peng L-N, Lin M-H, Chen L-K. Potential benefits of reducing medication-related anticholinergic burden for demented older adults: a prospective cohort study. Geriatr Gerontol Int 2013; 13: 694-700.
58. Low LF, Anstey KJ, Sachdev P. Use of medications with anticholinergic properties and cognitive function in a youngold community sample. Int J Geriatr Psychiatry 2009; 24: 578-84.
59. Torjesen I. Anticholinergic effects of common drugs are associated with increased mortality in over 65s. BMJ 2011; 342: d4037.